Cytrellis Biosystems has launched an updated version of its minimally invasive, in-office device that treats the signs of ...
D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular ...
The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback